U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C16H21NO4S
Molecular Weight 323.407
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of RISARESTAT

SMILES

CCCCCOC1=CC=C(C=C1OCC)C2SC(=O)NC2=O

InChI

InChIKey=CRPGRUONUFDYBG-UHFFFAOYSA-N
InChI=1S/C16H21NO4S/c1-3-5-6-9-21-12-8-7-11(10-13(12)20-4-2)14-15(18)17-16(19)22-14/h7-8,10,14H,3-6,9H2,1-2H3,(H,17,18,19)

HIDE SMILES / InChI

Description
Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/8562538

RISARESTAT is an aldose reductase inhibitor. It has been shown that topically applied RISARESTAT (CT-112) can penetrate the cornea at sufficient concentrations to inhibit the activity of AR in the lens and can be taken up by the endothelial cells. CT-112 was shown to improve the corneal epithelial barrier function in diabetic patients.

Originator

Curator's Comment: A European patent application was jointly filed by the Japanese companies Takeda and Senju and published in August 1981 http://worldwide.espacenet.com/publicationDetails/biblio?CC=EP&NR=0033617A2&KC=A2&FT=D # Takeda Chemical Industries, Ltd. and Senju Pharmaceutical Co.,Ltd.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
A randomised, placebo controlled clinical trial of the aldose reductase inhibitor CT-112 as management of corneal epithelial disorders in diabetic patients.
2005 Mar
Patents

Sample Use Guides

0.25% eye drops of RISARESTAT (CT-112) four times a day for 8 weeks.
Route of Administration: Topical
In Vitro Use Guide
Curator's Comment: Rat lenses were cultured in a medium containing either 30mM xylose or 30mM glucose. Inhibitory effect of RISARESTAT (CT-112), on the accumulation of sugar alcohols and the concentration of the drug in the lens was measured.
50% inhibition-concentration in the medium was 3.78-5.92 x 10(-7) M for RISARESTAT (CT-112), and the resulting concentration of drug in the lens was 21.19-24.63 nmole/g lens for CT-112.
Name Type Language
RISARESTAT
INN  
INN  
Official Name English
RISRESTAT
JAN  
Common Name English
CT-112
Code English
2,4-THIAZOLIDINEDIONE, 5-(3-ETHOXY-4-(PENTYLOXY)PHENYL)-
Systematic Name English
(±)-5-(3-ETHOXY-4-(PENTYLOXY)PHENYL)-2,4-THIAZOLIDINEDIONE
Systematic Name English
risarestat [INN]
Common Name English
RISRESTAT [JAN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C471
Created by admin on Fri Dec 15 16:25:19 GMT 2023 , Edited by admin on Fri Dec 15 16:25:19 GMT 2023
Code System Code Type Description
MESH
C051003
Created by admin on Fri Dec 15 16:25:19 GMT 2023 , Edited by admin on Fri Dec 15 16:25:19 GMT 2023
PRIMARY
CAS
79714-31-1
Created by admin on Fri Dec 15 16:25:19 GMT 2023 , Edited by admin on Fri Dec 15 16:25:19 GMT 2023
PRIMARY
PUBCHEM
133264
Created by admin on Fri Dec 15 16:25:19 GMT 2023 , Edited by admin on Fri Dec 15 16:25:19 GMT 2023
PRIMARY
EPA CompTox
DTXSID7048796
Created by admin on Fri Dec 15 16:25:19 GMT 2023 , Edited by admin on Fri Dec 15 16:25:19 GMT 2023
PRIMARY
ChEMBL
CHEMBL1983865
Created by admin on Fri Dec 15 16:25:19 GMT 2023 , Edited by admin on Fri Dec 15 16:25:19 GMT 2023
PRIMARY
FDA UNII
6I9DQB98QI
Created by admin on Fri Dec 15 16:25:19 GMT 2023 , Edited by admin on Fri Dec 15 16:25:19 GMT 2023
PRIMARY
INN
7936
Created by admin on Fri Dec 15 16:25:19 GMT 2023 , Edited by admin on Fri Dec 15 16:25:19 GMT 2023
PRIMARY
NCI_THESAURUS
C90847
Created by admin on Fri Dec 15 16:25:19 GMT 2023 , Edited by admin on Fri Dec 15 16:25:19 GMT 2023
PRIMARY
SMS_ID
300000034384
Created by admin on Fri Dec 15 16:25:19 GMT 2023 , Edited by admin on Fri Dec 15 16:25:19 GMT 2023
PRIMARY